AU2020404978A1 - CD206 modulators their use and methods for preparation - Google Patents
CD206 modulators their use and methods for preparation Download PDFInfo
- Publication number
- AU2020404978A1 AU2020404978A1 AU2020404978A AU2020404978A AU2020404978A1 AU 2020404978 A1 AU2020404978 A1 AU 2020404978A1 AU 2020404978 A AU2020404978 A AU 2020404978A AU 2020404978 A AU2020404978 A AU 2020404978A AU 2020404978 A1 AU2020404978 A1 AU 2020404978A1
- Authority
- AU
- Australia
- Prior art keywords
- alkyl
- compound
- phenyl
- aryl
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/80—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962950488P | 2019-12-19 | 2019-12-19 | |
| US62/950,488 | 2019-12-19 | ||
| PCT/US2020/065238 WO2021126923A1 (en) | 2019-12-19 | 2020-12-16 | Cd206 modulators their use and methods for preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2020404978A1 true AU2020404978A1 (en) | 2022-08-11 |
Family
ID=74184891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020404978A Pending AU2020404978A1 (en) | 2019-12-19 | 2020-12-16 | CD206 modulators their use and methods for preparation |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230056497A1 (https=) |
| EP (1) | EP4077297A1 (https=) |
| JP (2) | JP7801223B2 (https=) |
| CN (1) | CN115768757B (https=) |
| AU (1) | AU2020404978A1 (https=) |
| CA (1) | CA3165339A1 (https=) |
| WO (1) | WO2021126923A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210151945A (ko) | 2019-04-12 | 2021-12-14 | 립타이드 바이오사이언스, 인코포레이티드 | 대식세포 활성을 조정하기 위한 방법 |
| WO2023192935A1 (en) * | 2022-03-30 | 2023-10-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods and compositions for the treatment for inflammation and fibrosis in retinal neovascular diseases |
| WO2025247783A1 (en) | 2024-05-29 | 2025-12-04 | Syngenta Crop Protection Ag | Pesticidally active dihydro-benzoxazinone compounds |
| WO2025248032A1 (en) | 2024-05-31 | 2025-12-04 | Syngenta Crop Protection Ag | Pesticidally active indazole compounds |
| WO2025257072A1 (en) | 2024-06-14 | 2025-12-18 | Syngenta Crop Protection Ag | Pesticidally active 2-oxobenzimidazole compounds |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6897231B2 (en) | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
| US20050009876A1 (en) | 2000-07-31 | 2005-01-13 | Bhagwat Shripad S. | Indazole compounds, compositions thereof and methods of treatment therewith |
| DE10207843A1 (de) | 2002-02-15 | 2003-09-04 | Schering Ag | Mikrolia-Inhibitoren zur Unterbrechung von Interleukin 12 und IFN-gamma vermittelten Immunreaktionen |
| US20090209577A1 (en) | 2004-08-18 | 2009-08-20 | Pfizer Inc. | Novel Triazolopyridine Compounds |
| BRPI0514391A (pt) * | 2004-08-18 | 2008-06-10 | Pharmacia & Upjohn Co Llc | compostos de triazolopiridina para o tratamento de inflamação |
| ZA200704889B (en) | 2004-11-23 | 2008-09-25 | Celgene Corp | JNK inhibitors for treatment of CNS injury |
| WO2009086303A2 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| ES2642586T3 (es) * | 2009-07-27 | 2017-11-16 | Gilead Sciences, Inc. | Compuestos heterocíclicos condensados como moduladores de canales iónicos |
| EP2742046A1 (en) | 2011-08-12 | 2014-06-18 | F.Hoffmann-La Roche Ag | PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE |
| EP2818471A1 (en) * | 2013-06-27 | 2014-12-31 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Nitrogen bicyclic compounds as inhibitors for Scyl1 and Grk5 |
| US10016480B2 (en) | 2014-10-14 | 2018-07-10 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Peptide-based methods for treating pancreatic cancer |
| WO2016089977A1 (en) | 2014-12-03 | 2016-06-09 | Celgene Corporation | Substituted indazole compounds, compositions thereof, and methods of treatment therewith |
| US10730842B2 (en) * | 2015-09-03 | 2020-08-04 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Small molecule inhibitors of DYRK1A and uses thereof |
| US20220340983A1 (en) * | 2019-09-13 | 2022-10-27 | Massachustts Institute Of Technology | Systems and assays for identifying pu.1 inhibitors |
-
2020
- 2020-12-16 CA CA3165339A patent/CA3165339A1/en active Pending
- 2020-12-16 CN CN202080096478.2A patent/CN115768757B/zh active Active
- 2020-12-16 EP EP20842083.6A patent/EP4077297A1/en active Pending
- 2020-12-16 AU AU2020404978A patent/AU2020404978A1/en active Pending
- 2020-12-16 WO PCT/US2020/065238 patent/WO2021126923A1/en not_active Ceased
- 2020-12-16 JP JP2022537672A patent/JP7801223B2/ja active Active
- 2020-12-16 US US17/787,313 patent/US20230056497A1/en active Pending
-
2026
- 2026-01-05 JP JP2026000422A patent/JP2026053706A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4077297A1 (en) | 2022-10-26 |
| US20230056497A1 (en) | 2023-02-23 |
| JP2026053706A (ja) | 2026-03-25 |
| JP2023507610A (ja) | 2023-02-24 |
| JP7801223B2 (ja) | 2026-01-16 |
| WO2021126923A1 (en) | 2021-06-24 |
| CA3165339A1 (en) | 2021-06-24 |
| CN115768757B (zh) | 2025-07-11 |
| CN115768757A (zh) | 2023-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7394074B2 (ja) | 治療用化合物 | |
| CN104945401B (zh) | Ip化合物及它们在治疗中的应用 | |
| JP7801223B2 (ja) | Cd206モジュレーター、その使用、および調製方法 | |
| AU2022399372A1 (en) | Fused pyrimidine derivatives as kras oncoprotein inhibitors | |
| CN115873020A (zh) | Ras抑制剂 | |
| CN114980976A (zh) | 共价ras抑制剂及其用途 | |
| WO2024097559A1 (en) | 1,5-naphthyridine derivatives as kras oncoprotein inhibitors | |
| WO2018045956A1 (zh) | 苯并咪唑类化合物激酶抑制剂及其制备方法和应用 | |
| CN103896942A (zh) | 聚(adp-核糖)聚合酶(parp)的二氢吡啶并酞嗪酮抑制剂 | |
| AU2015369712A1 (en) | Mutant IDH1 inhibitors useful for treating cancer | |
| TW201917129A (zh) | 含吡唑基的三并環類衍生物、其製備方法和應用 | |
| CN115677730B (zh) | 8-氧-3-氮杂二环[3.2.1]辛烷类化合物或其盐及其制备方法和用途 | |
| CN113164481A (zh) | 环烷-1,3-二胺衍生物 | |
| CN104418867B (zh) | 作为PI3K/mTOR抑制剂的化合物,其制备方法和用途 | |
| JP2025503099A (ja) | ピリジン系誘導体、その製造方法及び使用 | |
| EP3893872A1 (en) | Organophosphorus-substituted compounds as c-met inhibitors and therapeutic uses thereof | |
| US20240002365A1 (en) | Pyridazine and 1,2,4-triazine derivatives as fgfr kinase inhibitors | |
| TW202430505A (zh) | 萘醯胺類化合物、其製備方法及其應用 | |
| US20240190864A1 (en) | Bruton's Tyrosine Kinase (BTK) INHIBITOR AND APPLICATION THEREOF | |
| EA031505B1 (ru) | СОЕДИНЕНИЯ 4Н-ПИРИДО[1,2-а]ПИРИМИДИН-4-ОНА | |
| HK40074236A (en) | Covalent ras inhibitors and uses thereof |